Relationship among NPM1 mutation, FAB type, and genetic alterations in AML
. | . | NPM1 . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
. | Total no. patients . | Mutation, no. (%)* . | Wild type, no. (%)† . | P . | ||||
| FAB subtype | .005 | |||||||
| M0 | 9 | 2 (22.2) | 7 (77.8) | |||||
| M1 | 54 | 17 (31.5) | 37 (68.5) | |||||
| M2 | 89 | 12 (13.5) | 77 (86.5) | |||||
| M3 | 15 | 0 (0) | 15 (100) | |||||
| M4 | 54 | 21 (38.9) | 33 (61.1) | |||||
| M5 | 19 | 9 (47.3) | 10 (52.7) | |||||
| M6 | 8 | 2 (25.0) | 6 (75.0) | |||||
| M7 | 9 | 1 (11.1) | 8 (88.9) | |||||
| Cytogenetics | <.001 | |||||||
| t(8;21) | 31 | 0 (0) | 31 (100) | |||||
| inv(16) | 8 | 1 (12.5) | 7 (87.5) | |||||
| t(15;17) | 15 | 0 (0) | 15 (100) | |||||
| t(9;22) | 3 | 1 (33.3) | 2 (66.7) | |||||
| del(5) | 7 | 0 (0) | 7 (100) | |||||
| del(7) | 5 | 0 (0) | 5 (100) | |||||
| Others | 43 | 5 (11.6) | 38 (88.4) | |||||
| Normal | 97 | 46 (47.4) | 51 (52.6) | |||||
| Unknown | 48 | 11 (22.9) | 37 (77.1) | |||||
| FLT3 | ||||||||
| Mutations, total | 67 | 39 (58.2) | 28 (41.8) | <.001 | ||||
| ITD | 58 | 35 (60.3) | 23 (39.7) | <.001‡ | ||||
| D835 | 9 | 4 (44.4) | 5 (55.6) | .028‡ | ||||
| Wild type | 190 | 25 (13.2) | 165 (86.8) | |||||
| TP53 | NS | |||||||
| Mutation | 16 | 2 (12.5) | 14 (87.5) | |||||
| Wild type | 227 | 58 (25.6) | 169 (74.4) | |||||
| Not done | 14 | 5 (35.7) | 10 (64.3) | |||||
| NRAS | NS | |||||||
| Mutation | 34 | 9 (26.5) | 25 (73.5) | |||||
| Wild type | 202 | 48 (23.8) | 154 (76.2) | |||||
| Not done | 21 | 7 (33.3) | 14 (66.7) | |||||
| MLL-TD | NS | |||||||
| Mutation | 17 | 2 (11.8) | 15 (88.2) | |||||
| Wild type | 130 | 33 (25.4) | 97 (74.6) | |||||
| Not done | 110 | 29 (26.4) | 81 (73.6) | |||||
| Numbers and percentages of 257 patients with AML are shown by FAB type; cytogenetics; and FLT3, TP53, NRAS, and MLL-TD mutations, according to NPM1 mutation. | ||||||||
| NS indicates not significant. | ||||||||
. | . | NPM1 . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
. | Total no. patients . | Mutation, no. (%)* . | Wild type, no. (%)† . | P . | ||||
| FAB subtype | .005 | |||||||
| M0 | 9 | 2 (22.2) | 7 (77.8) | |||||
| M1 | 54 | 17 (31.5) | 37 (68.5) | |||||
| M2 | 89 | 12 (13.5) | 77 (86.5) | |||||
| M3 | 15 | 0 (0) | 15 (100) | |||||
| M4 | 54 | 21 (38.9) | 33 (61.1) | |||||
| M5 | 19 | 9 (47.3) | 10 (52.7) | |||||
| M6 | 8 | 2 (25.0) | 6 (75.0) | |||||
| M7 | 9 | 1 (11.1) | 8 (88.9) | |||||
| Cytogenetics | <.001 | |||||||
| t(8;21) | 31 | 0 (0) | 31 (100) | |||||
| inv(16) | 8 | 1 (12.5) | 7 (87.5) | |||||
| t(15;17) | 15 | 0 (0) | 15 (100) | |||||
| t(9;22) | 3 | 1 (33.3) | 2 (66.7) | |||||
| del(5) | 7 | 0 (0) | 7 (100) | |||||
| del(7) | 5 | 0 (0) | 5 (100) | |||||
| Others | 43 | 5 (11.6) | 38 (88.4) | |||||
| Normal | 97 | 46 (47.4) | 51 (52.6) | |||||
| Unknown | 48 | 11 (22.9) | 37 (77.1) | |||||
| FLT3 | ||||||||
| Mutations, total | 67 | 39 (58.2) | 28 (41.8) | <.001 | ||||
| ITD | 58 | 35 (60.3) | 23 (39.7) | <.001‡ | ||||
| D835 | 9 | 4 (44.4) | 5 (55.6) | .028‡ | ||||
| Wild type | 190 | 25 (13.2) | 165 (86.8) | |||||
| TP53 | NS | |||||||
| Mutation | 16 | 2 (12.5) | 14 (87.5) | |||||
| Wild type | 227 | 58 (25.6) | 169 (74.4) | |||||
| Not done | 14 | 5 (35.7) | 10 (64.3) | |||||
| NRAS | NS | |||||||
| Mutation | 34 | 9 (26.5) | 25 (73.5) | |||||
| Wild type | 202 | 48 (23.8) | 154 (76.2) | |||||
| Not done | 21 | 7 (33.3) | 14 (66.7) | |||||
| MLL-TD | NS | |||||||
| Mutation | 17 | 2 (11.8) | 15 (88.2) | |||||
| Wild type | 130 | 33 (25.4) | 97 (74.6) | |||||
| Not done | 110 | 29 (26.4) | 81 (73.6) | |||||
| Numbers and percentages of 257 patients with AML are shown by FAB type; cytogenetics; and FLT3, TP53, NRAS, and MLL-TD mutations, according to NPM1 mutation. | ||||||||
| NS indicates not significant. | ||||||||